Optimised Robust Treatment Plans for Prostate Cancer Focal Brachytherapy

Abstract Focal brachytherapy is a clinical procedure that can be used to treat low-risk prostate cancer with reduced side-effects compared to conventional brachytherapy. Current practice is to man- ually plan the placement of radioactive seeds inside the prostate to achieve a desired treatment dose. Problems with the current practice are that the manual planning is time-consuming and high doses to the urethra and rectum cause undesirable side-effects. To address this problem, we have designed an optimisation algorithm that constructs treatment plans which achieve the desired dose while minimizing dose to organs at risk. We also show that these seed plans are robust to post-operative movement of the seeds within the prostate.

[1]  Jean Pouliot,et al.  The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. , 2004, International journal of radiation oncology, biology, physics.

[2]  Seong Ki Mun,et al.  Modeling and mapping of prostate cancer , 2000, Comput. Graph..

[3]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[4]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[5]  R. J. Gallagher,et al.  Treatment planning for brachytherapy: an integer programming model, two computational approaches and experiments with permanent prostate implant planning. , 1999, Physics in medicine and biology.

[6]  Annette Haworth,et al.  Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. , 2013, Brachytherapy.

[7]  Adam P Dicker,et al.  Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.

[8]  Mark Emberton,et al.  Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer , 2012, BJU international.

[9]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[10]  Martin Bues,et al.  Effect of random seed placement error in permanent transperineal prostate seed implant. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Wayne M Butler,et al.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. , 2012, Brachytherapy.

[12]  Howard Pai,et al.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.

[13]  Y. Yu,et al.  Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. , 2001, International journal of radiation oncology, biology, physics.

[14]  Annette Haworth,et al.  Assessment of i-125 prostate implants by tumor bioeffect. , 2004, International journal of radiation oncology, biology, physics.

[15]  J Pouliot,et al.  Monte Carlo simulations of prostate implants to improve dosimetry and compare planning methods. , 1999, Medical physics.

[16]  Jeremy L Millar,et al.  Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Nathan Lawrentschuk,et al.  The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.

[18]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.